ATE423778T1 - Verfahren zur herstellung von anthranilsäurederivat-hydrat - Google Patents

Verfahren zur herstellung von anthranilsäurederivat-hydrat

Info

Publication number
ATE423778T1
ATE423778T1 AT03727661T AT03727661T ATE423778T1 AT E423778 T1 ATE423778 T1 AT E423778T1 AT 03727661 T AT03727661 T AT 03727661T AT 03727661 T AT03727661 T AT 03727661T AT E423778 T1 ATE423778 T1 AT E423778T1
Authority
AT
Austria
Prior art keywords
hydrate
acid derivative
anthranilic acid
filtrate
pharmaceutically acceptable
Prior art date
Application number
AT03727661T
Other languages
English (en)
Inventor
David HAYMAN
Michael Wright
Original Assignee
Xenova Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenova Ltd filed Critical Xenova Ltd
Application granted granted Critical
Publication of ATE423778T1 publication Critical patent/ATE423778T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03727661T 2002-05-14 2003-05-13 Verfahren zur herstellung von anthranilsäurederivat-hydrat ATE423778T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37975902P 2002-05-14 2002-05-14

Publications (1)

Publication Number Publication Date
ATE423778T1 true ATE423778T1 (de) 2009-03-15

Family

ID=29420557

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03727661T ATE423778T1 (de) 2002-05-14 2003-05-13 Verfahren zur herstellung von anthranilsäurederivat-hydrat

Country Status (11)

Country Link
US (1) US7524861B2 (de)
EP (1) EP1506188B1 (de)
JP (1) JP4464814B2 (de)
KR (1) KR101060971B1 (de)
CN (1) CN100349888C (de)
AT (1) ATE423778T1 (de)
AU (1) AU2003233899B2 (de)
BR (1) BR0309990A (de)
CA (1) CA2485430C (de)
DE (1) DE60326341D1 (de)
WO (1) WO2003095447A1 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100557093B1 (ko) 2003-10-07 2006-03-03 한미약품 주식회사 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법
MX341797B (es) * 2004-06-24 2016-09-02 Vertex Pharmaceuticals Incorporated * Moduladores de transportadores con casete de union con atp.
US8354427B2 (en) * 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
FR2873585B1 (fr) * 2004-07-27 2006-11-17 Aventis Pharma Sa Nouvelles formulations galeniques de principes actifs
EP1979367A2 (de) * 2005-12-24 2008-10-15 Vertex Pharmaceuticals Incorporated Chinolin-4-on-derivate als modulatoren von abc-transportern
LT1993360T (lt) * 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
GB0706072D0 (en) * 2007-03-28 2007-05-09 Sterix Ltd Compound
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
MX384179B (es) 2009-03-20 2025-03-14 Vertex Pharma Proceso para producir moduladores del regulador de conductancia transmembrana de fibrosis quística.
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
JP2015511583A (ja) 2012-02-27 2015-04-20 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated 薬学的組成物およびその投与
MD4684B1 (ro) 2013-07-30 2020-03-31 Gilead Connecticut INc. Formulări pe bază de imidazopirazine în calitate de inhibitori SYK
ES2822285T3 (es) 2013-07-30 2021-04-30 Kronos Bio Inc Polimorfo de inhibidores de SYK
TWI735853B (zh) 2013-12-23 2021-08-11 美商克洛諾斯生技有限公司 脾酪胺酸激酶抑制劑
CN103804352B (zh) * 2014-01-23 2017-06-13 中国药科大学 三氮唑苯乙基四氢异喹啉类化合物及其制备方法和应用
EP3204358B1 (de) 2014-10-07 2018-09-19 Vertex Pharmaceuticals Incorporated Cokristalle von modulatoren des transmembrankonduktanzregulators bei zystischer fibrose
CN104327046B (zh) * 2014-10-14 2017-11-17 中国药科大学 三氮唑‑n‑乙基四氢异喹啉类化合物及其制备方法和应用
CN104434947B (zh) * 2014-11-07 2016-11-09 滨州医学院附属医院 一种抗胆管癌的药物组合物及其应用
EP3378858A1 (de) * 2017-03-21 2018-09-26 Bioprojet Tetrahydrat von h3-ligand, verfahren zu dessen herstellung und pharmazeutische zusammensetzungen damit
US11384082B2 (en) 2017-08-25 2022-07-12 Kronos Bio, Inc. Hydrates of polymorphs of 6-(1H-indazol-6-YL)-N-(4-morpholinophenyl)-2,3-dihydroimidazo[1,2-A]pyrazin-8-amine bisemsylate as Syk inhibitors
US11339168B2 (en) 2019-02-22 2022-05-24 Kronos Bio, Inc. Crystalline forms of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as Syk inhibitors
KR20230104614A (ko) * 2020-10-07 2023-07-10 아테넥스, 인크. 아세트아미도-페닐벤즈아미드 유도체 및 그의 사용 방법
CN112724124A (zh) * 2021-01-18 2021-04-30 林剑雄 4-羟基喹啉类衍生物及其制备方法和在抗肿瘤药物中的应用
CN117304105A (zh) * 2023-08-18 2023-12-29 中国科学院基础医学与肿瘤研究所(筹) 一种靶向抑制ABCB1(P-gp)的化合物及制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT68856A (en) * 1991-01-11 1995-08-28 Glaxo Lab Sa Acridine derivatives, pharmaceutical compositions comprising the same compouds as effective substances and a process for producing the compounds and the pharmaceutical compositions
GB9717576D0 (en) 1997-08-19 1997-10-22 Xenova Ltd Pharmaceutical compounds
HUP0001531A3 (en) * 1996-10-18 2000-09-28 Xenova Ltd Slough Anthranilic acid derivatives as multi drug resistance modulators

Also Published As

Publication number Publication date
EP1506188B1 (de) 2009-02-25
KR101060971B1 (ko) 2011-09-01
DE60326341D1 (de) 2009-04-09
AU2003233899B2 (en) 2009-03-12
CA2485430A1 (en) 2003-11-20
CN100349888C (zh) 2007-11-21
JP2005538051A (ja) 2005-12-15
CA2485430C (en) 2011-12-06
US20050222199A1 (en) 2005-10-06
KR20050009706A (ko) 2005-01-25
AU2003233899A1 (en) 2003-11-11
WO2003095447A1 (en) 2003-11-20
EP1506188A1 (de) 2005-02-16
JP4464814B2 (ja) 2010-05-19
US7524861B2 (en) 2009-04-28
CN1665806A (zh) 2005-09-07
BR0309990A (pt) 2005-02-22

Similar Documents

Publication Publication Date Title
ATE423778T1 (de) Verfahren zur herstellung von anthranilsäurederivat-hydrat
CN104936961B (zh) (1s,4s,5s)-4-溴-6-氧杂二环[3.2.1]辛-7-酮的制备方法
RU2753492C1 (ru) Хиральное разделение смеси энантиомеров никотина
NO20052912L (no) Metode for fremstilling av krystallinske former for optiske enantiomerer av modafinil
US11897843B2 (en) Process for the preparation of enantiomerically enriched 3-aminopiperidine
ATE366725T1 (de) Verfahren zur herstellung von gereinigten 1,3- substituierten imidazoliumsalzen
ES2706314T3 (es) Método para la producción de praziquantel y precursores del mismo
JP2010090174A (ja) 新規ナテグリニド結晶
ATE515496T1 (de) Verfahren zur herstellung von enantiomerenangereicherter indolin-2-carbonsäure
RU2006102357A (ru) Способ управления кристаллической структурой ризедроната
RU2387656C2 (ru) Способ получения гидробромида галантамина
ATE297933T1 (de) Ein verfahren zur herstellung von hochreinem cefpodoxim-proxetil
ATE316082T1 (de) Prozess zur herstellung von r(+)alpha-liponsäure
ATE325797T1 (de) Verfahren zur herstellung von hochreinem triethylendiamin
DE50307171D1 (de) Verfahren zur herstellung von 3-amidinophenylalanin-derivaten
ATE403658T1 (de) Verfahren zur herstellung einer lösung von reinem triethylendiamin (teda)
ATE370950T1 (de) Verfahren zur herstellung von (1s,4r)-cis-4-(2- amino-6-chlor-9h-purin-9-yl)-2-cyclopenten-1- methanol
DE602006015241D1 (de) Verbessertes verfahren zur herstellung von rivastigmin
DE602004020050D1 (de) Verfahren zur herstellung substituierter imidazolderivate und in dem verfahren verwendete zwischenprodukte
JPH1036327A (ja) 1−(3−メトキシフェニル)エチルアミンの光学活性体の製造方法
ATE375355T1 (de) Verfahren zur herstellung von cefpodoxim-proxetil
WO2005012278A3 (en) Process for purifying citalopram using polybasic acids
JP2009062392A (ja) 環化法
RU2019104860A (ru) Способ разделения солей баклофена
BR112020009568A2 (pt) Método de produção de composto intermediário para síntese de medicamento

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties